Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Patrick Durez, ACR 2022: Adverse event reporting in rheumatoid arthritis clinical trials – an analysis of long-term filgotinib integrated safety data

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 22nd 2022

Different methods such as exposure-adjusted incidence rates and exposure-adjusted event rates are used to report adverse events in rheumatoid arthritis (RA) clinical trials, this study compared different methodologies of reporting in long-term filgotinib integrated safety data. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) around the aims, design and findings of the study.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA.‘ (Abstract number: 0278) was presented at the ACR Convergence, November 10–14, 2022.

Questions

  1. Could you explain the terms exposure-adjusted incidence rates (EAIRs) and exposure-adjusted event rates (EAERs) in reporting treatment-emergent adverse events in clinical trials? (0:19)
  2. Which of these is most commonly used in RA studies and how can this affect the outcome evaluation? (1:01)
  3. What were the aims and design of your study? (1:37)
  4. What were the findings of the study? (2:06)
  5. What is the key take-home message for future clinical trial design? (2:40)

Disclosures: Patrick Durez has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup